Title
Impact of pathological features of brain metastases in prognosis
Date Issued
01 May 2018
Access level
metadata only access
Resource Type
journal article
Author(s)
CASTAÑEDA ALTAMIRANO, CARLOS ARTURO
CASTILLO GARCIA, MILUSKA
Bernabe L.
Sanchez J.
CASAVILCA ZAMBRANO, SANDRO ANGEL ANIBAL
García-Corrochano P.
Ponce J.
Villa-Robles M.
Lopez C.
Publisher(s)
Future Medicine Ltd.
Abstract
Aim: To evaluate the prognostic value of tumor-infiltrating lymphocytes (TILs) and Ki67 in brain metastasis lesions, and the effect of adding them to variables of graded prognostic assessment score. Patients & methods: Clinicopathological information from 111 medical charts of brain metastasis patients was obtained, and TIL distribution (n = 84), Ki67 index (n = 79) and CD3 TIL (n = 64) were prospectively evaluated. Results: Most frequent TIL pattern was perivascular (67.8%), and median Ki67 and CD3 TIL percents were 30 and 4.8%, respectively. Ki67 ≥15 was associated with shorter survival (p = 0.018) but CD3 TIL was not (p = 0.870). The highest graded prognostic assessment score was not associated with survival (p = 0.648), however, those with low Ki67 and high score was associated with better outcome (p = 0.007). Conclusion: High Ki67 index in brain metastasis carries a worse prognosis.
Start page
475
End page
485
Volume
12
Issue
5
Language
English
OCDE Knowledge area
Oncología Neurología clínica
Scopus EID
2-s2.0-85046846243
PubMed ID
Source
Biomarkers in Medicine
ISSN of the container
17520363
Source funding
Olympus
Instituto Nacional de Enfermedades Neoplasicas Institutional Review Board
Sponsor(s)
Funding text 1 This study was possible thanks to the use of the Automatic Multispectral Imaging System (Olympus BX63) financed by the Pro-grama Nacional de Innovación para la Competitividad y Productividad (Innovate Peru), under the contract 317-PNICP-EC-2014. The authors would like to express their gratitude to V Flores for his support in staining preparation of tumor sections; and to C Flores for a biostatistics review. Funding text 2 Informed consent was obtained from each study participant. This study was reviewed and approved by the Instituto Nacional de Enfermedades Neoplasicas Institutional Review Board.
Sources of information: Directorio de Producción Científica Scopus